30% revenue growth for FY26
Management expects full-year revenue growth of 30%, including ~15% organic and ~15% from M&A, with ~₹500 crore of acquired revenue recognized.
ENTERO / guidance tracker
Keep management guidance in view.
Entero Healthcare Solutions · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
4%+ EBITDA margin for FY26
Full-year EBITDA margin target of over 4%, driven by operating leverage, product mix improvement, and procurement efficiencies.
Working capital target of 60 days by FY26 end
Targeting a 10% reduction in working capital days from 66 to 60 by end of FY26 through ERP and data science initiatives.
Tax rate of 17-18% for FY26
Effective tax rate expected to remain in the 17-18% range for the full year due to tax efficiency measures.
FY27 consolidated revenue growth of 23% (ex-new M&A)
Revenue growth target of 23% YoY, excluding any new acquisitions, driven by calendarization of past deals and organic growth.
FY27 EBITDA margin target of 5%
EBITDA margin guided to 5% for FY27, up from 4% in FY26, supported by gross margin expansion and operating leverage.
Operating cash flow conversion of at least 50% of EBITDA
Target to convert at least 50% of EBITDA into operating cash flow in FY27, reflecting working capital discipline.
Minority interest to be ~25% of PAT before minority
Minority interest expected to normalize to ~25% of PAT (pre-minority) in FY27, down from 38% in Q4 FY26.